Mark Chin - Director at Enliven Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Director
Issuer Symbol
ELVN on Nasdaq
All Insider Reports
All Insider Reports

There are no Buy or Sell transactions made by Mark Chin since 01 Jan 2025

Holdings reported by Mark Chin for Enliven Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 2,344,072 $35,477,530 $15.14 02 Jun 2022 By entities affiliated with Arix Bioscience plc
Stock Options (Right to Buy) 8,500 02 Jun 2022 Direct Common Stock

Transactions reported by Mark Chin for Enliven Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.